Troglitazone and d-chiroinositol have been shown to exert antidiabetic effects by either potentiating or mimicking insulin action. We studied whether pretreatment with these compounds can prevent the deleterious effects of glucosamine on insulin action that may play an important role in hyperglycemia-induced insulin resistance. Normal Wistar rats were pretreated with troglitazone (100 mg/kg/d), d-chiroinositol (100 mg/kg/d), or placebo (saline) for 7 days. Glucosamine (50 μmol/kg/min) was then infused for 210 minutes, and a euglycemic glucose clamp was performed during the last 120 minutes. Pretreatment with troglitazone or d-chiroinositol had no effect on fasting plasma glucose or insulin or basal hepatic glucose output (HGO). Under the euglycemic-hyperinsulinemic (956 +/- 93 pmol/L) clamp condition, HGO in glucosamine-infused placebo-treated rats was not suppressed, but instead was increased over the basal level, indicative of hepatic insulin resistance. In contrast, HGO failed to increase during glucosamine infusion in rats pretreated with troglitazone but was not normally suppressed. This may indicate a partial improvement in the hepatic insulin resistance. d-Chiroinositol pretreatment had no effect on the glucosamine-induced increase in HGO. The glucose disposal rate (GDR) was 25% lower in rats infused with glucosamine versus saline-infused rats (25.5 +/- 2.5 v 34.1 +/- 2.0 mg/kg/min), indicative of peripheral insulin resistance. Pretreatment with d-chiroinositol (34.5 +/- 2.3 mg/kg/min) prevented the glucosamine-induced decrease in the GDR, indicating an improvement in peripheral insulin resistance. Troglitazone (25.2 +/- 3.3 mg/kg/min) was without effect. In conclusion, (1) in normal control rats, glucosamine infusion induced hepatic and peripheral insulin resistance; (2) d-chiroinositol, but not troglitazone, pretreament prevented glucosamine-induced peripheral insulin resistance; and (3) troglitazone, but not d-chiroinositol, partially blocked the glucosamine-induced hepatic insulin resitance. d-Chiroinositol may provide a novel pharmacological approach to hexosamine-induced peripheral insulin resistance.